Good point. There is some evidence that APRIL levels are inversely correlated with disease activity (see reference below). Consequently, it may not be an advantage to inhibit APRIL or the BLYS/APRIL heterodimer. Time and clinical trials will tell. <A HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15308519&query_hl=3&itool=pubmed_docsum" target="_blank">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...</A>